Metabolic and alcohol-associated liver disease (MetALD): a representation of duality

npj gut and liver., Год журнала: 2025, Номер 2(1)

Опубликована: Янв. 10, 2025

MetALD is a recently coined term that refers to systemic entity describe patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and simultaneous moderate alcohol consumption. The deleterious association of risk factors synergistically increases the development steatohepatitis, fibrosis, hepatocellular carcinoma (HCC). Despite its increasing incidence, pathophysiological mechanisms triggering damage in remain unclear. This review aims summarize prevalence, pathophysiology MetALD, taking into account latest clinical translational aspects.

Язык: Английский

---

Non-invasive testing in metabolic dysfunction-associated steatotic liver disease

Frontiers in Medicine, Год журнала: 2024, Номер 11

Опубликована: Ноя. 13, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty (NAFLD), is a leading cause of chronic disease, affecting up 30% the global population. MASLD strongly associated with metabolic risk factors such obesity and type 2 diabetes, can progress advanced stages including cirrhosis hepatocellular carcinoma. Early diagnosis accurate staging fibrosis are critical in managing preventing complications. While biopsy has long been considered gold standard for assessing fibrosis, it invasive carries risks. In response, non-invasive tests (NITs) have emerged essential alternatives monitoring MASLD. Key methods include blood-based biomarkers Fibrosis-4 (FIB-4) score, NAFLD Fibrosis Score (NFS), Enhanced Liver (ELF) test, well imaging modalities like vibration-controlled transient elastography (VCTE) magnetic resonance (MRE). These provide safer, more accessible identifying guiding clinical management. They integral severity, treatment decisions, progression, particularly light emerging therapies. NITs become increasingly recommended by guidelines they reduce need procedures biopsy, improving patient care outcomes. conclusion, testing plays crucial role effective management MASLD, offering reliable while minimizing risks traditional methods.

Язык: Английский

---

Is liver fibrosis more advanced in MetALD than in MASLD?

Journal of Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Июль 1, 2024

Язык: Английский

---

Liver and Atherosclerotic Risk of Alcohol Consumption in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Atherosclerosis, Год журнала: 2025, Номер 403, С. 119161 - 119161

Опубликована: Март 7, 2025

Язык: Английский

---

Impact of Cardiometabolic Risk Factors on Hepatic Fibrosis and Clinical Outcomes in MASLD: A Population-based Multi-Cohort Study

JHEP Reports, Год журнала: 2025, Номер unknown, С. 101388 - 101388

Опубликована: Март 1, 2025

Язык: Английский

---

MetALD: New Perspectives on an Old Overlooked Disease

Liver International, Год журнала: 2025, Номер 45(5)

Опубликована: Апрель 3, 2025

ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated (ALD) are the major contributors to burden globally. The rise in these conditions is linked obesity, type 2 diabetes, metabolic syndrome increased alcohol consumption. MASLD ALD share risk factors, pathophysiology histological features but differ their thresholds for use, definition does not require presence of dysfunction. A recent multi‐society consensus overhauled nomenclature steatosis introduced term MetALD describe patients with dysfunction who drink more than those less ALD. This new terminology aims enhance understanding management poses challenges, such as need accurately measure consumption research clinical practice settings. Recent studies show that has significant implications patient management, it associated mortality risks severe outcomes compared alone. face progression, cancer cardiovascular disease. diagnosis involves adequate quantification use through standardised questionnaires and/or biomarkers well proper assessment stage progression using non‐invasive tools including serologic markers, imaging, elastography techniques genetic testing. Effective requires addressing both alcohol‐related factors improve outcomes. review intends provide a comprehensive overview MetALD, covering pathogenesis, potential diagnostic approaches, strategies emerging therapies.

Язык: Английский

---

Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in health check‐up

Hepatology Research, Год журнала: 2024, Номер 55(2), С. 191 - 199

Опубликована: Окт. 4, 2024

Abstract Aims The multisociety consensus nomenclature has introduced steatotic liver disease (SLD) with diverse subclassifications, which are metabolic dysfunction‐associated (MASLD), dysfunction and alcohol‐associated (MetALD), (ALD), specific etiology, cryptogenic. We investigated their prevalence, as per the new definition, in individuals undergoing health check‐ups. Additionally, we analyzed distribution of Fibrosis‐4 (FIB‐4) index vibration‐controlled transient elastography (VCTE)‐derived stiffness measurement (LSM) for MASLD. Methods In this cross‐sectional study, 6530 subjects a check‐up Japan were included. Conventional B‐mode ultrasound was carried out on all subjects, those MASLD underwent VCTE. Results prevalence SLD 39.5%, comprising 28.7%, MetALD 8.6%, ALD 1.2%, etiology 0.3%, cryptogenic 0.7%. Subjects VCTE‐derived LSM ≥8 kPa constituted 2.1% FIB‐4 ≥1.3 showed that sensitivity, specificity, positive predictive value (PPV), negative diagnosing 60.6%, 77.0%, 5.3%, 98.9%, respectively. referral rate to specialists 23.8% using ≥1.30. “FIB‐4 <65 years ≥2.0 ≥65 years” higher PPV (6.7%) lower (17.1%) compared ≥1.3, but sensitivity (54.5%) did not show adequate diagnostic capability noninvasive test kPa. Conclusions Acknowledging selection bias hepatology centers, undertook prospective study. Although proves be convenient marker, it might perform well primary screening tool fibrosis general population (UMIN Clinical Trials Registry No. UMIN000035188).

Язык: Английский

---

Reply to “Is liver fibrosis more advanced in MetALD than in MASLD?”

Journal of Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Сен. 1, 2024

Язык: Английский

---